Zobrazeno 1 - 10
of 152
pro vyhledávání: '"J. Carl Barrett"'
Autor:
Miika J. Ahdesmäki, Brad A. Chapman, Pablo Cingolani, Oliver Hofmann, Aleksandr Sidoruk, Zhongwu Lai, Gennadii Zakharov, Mikhail Rodichenko, Mikhail Alperovich, David Jenkins, T. Hedley Carr, Daniel Stetson, Brian Dougherty, J. Carl Barrett, Justin H. Johnson
Publikováno v:
PeerJ, Vol 5, p e3166 (2017)
Sensitivity of short read DNA-sequencing for gene fusion detection is improving, but is hampered by the significant amount of noise composed of uninteresting or false positive hits in the data. In this paper we describe a tiered prioritisation approa
Externí odkaz:
https://doaj.org/article/c805a6e27ffa47ae840cea70b9209afb
Autor:
Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Publikováno v:
Scientia
Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may fail because of difficulties within the testing procedure. Optimiz
Autor:
Jan Budczies, David Fabrizio, H. Mellert, Mark Li, M. Butler, Phillip Stafford, K. Eyring, Diana Merino Vega, Mark Stewart, Dinesh Cyanam, Kristen Meier, Chen Zhao, Paul M. Williams, Justin Newberg, Warren Tom, Sarabjot Pabla, Ethan Sokol, A. Stenzinger, V.R. Gregersen, Vincent Funari, P. Beer, Roberto Salgado, Lisa M. McShane, G. Pestano, Jen-Hao Cheng, L.K. Bruce, Mingchao Xie, Laura M. Yee, J. Carl Barrett, Jeffrey M. Conroy, Laura Lasiter, R. Samara, Victor J. Weigman, George Green, Jonathan F. Baden, Tomas Vilimas, Jeff Allen, Matthew D. Hellmann, K.C. Valkenburg, Ahmet Zehir, A. J. Lazar, Elizabeth P. Garcia, Laura E. MacConaill, Laurel Keefer, Shu-Jen Chen, X.Z. Wang, Li Chen, A. Pallavajjalla, Yingdong Zhao, Q. Xie
Publikováno v:
Annals of Oncology. 32:1626-1636
Background Tumor mutational burden (TMB) measurements aid in identifying patients who are likely to benefit from immunotherapy; however, there is empirical variability across panel assays and factors contributing to this variability have not been com
Autor:
Robert T. McCormack, Daniel Stetson, Dana E. Connors, J. Carl Barrett, Kenneth D. Cole, Steven P. Lund, Chris Karlovich, Thomas Forbes, P. Mickey Williams, Megan H. Cleveland, Laura M. Yee, Christie J. Lau, Cloud P. Paweletz, Gary J. Kelloff, Benoit Destenaves, Hua-Jun He, Susan M. Keating
Publikováno v:
JCO Precision Oncology
PURPOSEWe report the results from a Foundation for the National Institutes of Health Biomarkers Consortium project to address the absence of well-validated quality control materials (QCMs) for circulating tumor DNA (ctDNA) testing. This absence is co
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Sonia Iyer, James Conway, Deanna Russell, Avinash Reddy, Jan Cosaert, Simon Barry, Marlene Dressman, Ilhem Mensi, Boaz Aronson, Jane Peters, Helen Ambrose, Keunchil Park, Patrick Forde, Benjamin Besse, John V. Heymach, J. Carl Barrett
Publikováno v:
Cancer Research. 83:CT039-CT039
Background: Promising clinical activity has been described with the combination of ceralasertib (oral ATR inhibitor) and durvalumab (anti-PD-L1 mAb) in patients with NSCLC who have progressed on prior anti-PD-(L)1 immunotherapy (HUDSON, NCT03334617)
Autor:
Harriet Kluger, J Carl Barrett, Justin F Gainor, Omid Hamid, Michael Hurwitz, Theresa LaVallee, Rebecca A Moss, Roberta Zappasodi, Ryan J Sullivan, Hussein Tawbi, Elad Sharon
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e005921
Immunotherapy is the standard of care for several cancers and the field continues to advance at a rapid pace, with novel combinations leading to indications in an increasing number of disease settings. Durable responses and long-term survival with im
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef1b73ebf29f9c68ebeb0c64bfd3c8b
https://www.repository.cam.ac.uk/handle/1810/331769
https://www.repository.cam.ac.uk/handle/1810/331769
Autor:
A. Hughes, Patricia McCoon, Stephen Fawell, Gayathri Bommakanti, Simon T. Barry, Deanna A. Mele, Larissa S. Carnevalli, Christopher Womack, Michael Collins, Nanhua Deng, Lukasz Magiera, Mingchao Xie, J. Carl Barrett, Richard Woessner, Srimathi S. Srinivasan, Deanna L. Russell, Shaun E Grosskurth, Corinne Reimer, Maneesh Singh, Minwei Ye, Theresa Proia, Matthew Griffin, Susan Cantin
Publikováno v:
Clinical Cancer Research. 26:6335-6349
Purpose: Danvatirsen is a therapeutic antisense oligonucleotide (ASO) that selectively targets STAT3 and has shown clinical activity in two phase I clinical studies. We interrogated the clinical mechanism of action using danvatirsen-treated patient s
Autor:
Fabiola Cecchi, Natasha Viglianti, Marlon Rebelatto, Norah J Shire, Simon T Barry, Tsveta Milenkova, Elizabeth Croydon, Danielle Carroll, J Carl Barrett
Publikováno v:
Journal of Clinical Oncology. 41:194-194
194 Background: Although regularly used in breast and gastric cancer, HER2 testing is not routinely performed in colorectal cancer (CRC). Immunohistochemistry (IHC) and in situ hybridization (ISH) scoring have not been optimized for assessment of HER